GlaxoSmithKline Plans to Produce 1 Billion Doses of Its Pandemic Vaccine Adjuvant in 2021

GlaxoSmithKline Plans to Produce 1 Billion Doses of Its Pandemic Vaccine Adjuvant in 2021

Simply put, adjuvants make vaccines work better; this one could be useful in conjunction with a number of SARS-CoV-2 vaccine candidates.